Rosenstock et al. published the results of a phase 3 clinical trial of tirzepatide, a dual GIP and GLP-1 receptor agonist, in patients with T2DM, showing significant results in glycemic control and weight loss (Rosenstock et al., 2021). This evidence concerns the gene GLP1R and type 2 diabetes mellitus.